Why Business Fundamentals Belong in Every Life Sciences Career

Sep 22, 2026 | Pharma

Image Source: Julia Koblitz via Unsplash
Independent Contributor
Written by: Professor David Falzani MBE, President
On behalf of: Engineers and Scientists in Business Fellowship (ESBF)

As a life scientist you might not have considered a business education. You are good at what you do, you may have no ambition to run a company or sit at a boardroom table. So why spend time on business fundamentals?

The honest answer is that deep technical expertise is exactly what the sector needs, and no one is suggesting you give it up. However, even if you stay a research scientist for your whole career, the reality of modern life sciences is that you will rarely work alone.

Whether you are in a university group or a spin-out, you will be part of a team, which will include people who are not scientists: engineers, intellectual property specialists, colleagues in the technology transfer office (TTO). Eventually you will be asked a question about the commercial side of the work or find yourself presenting in front of investors. The more you understand how those people think, the more effective you become in every one of those conversations.

A sector that begins with investors and ends in a deal

This matters more in life sciences than in almost any other field, because of the way our success stories tend to unfold. Long before a therapy or a device reaches FDA approval, a life science company may need to secure significant funding, build partnerships, protect intellectual property, generate evidence and make choices about how the technology will reach patients or customers.

Successful life sciences companies can follow many routes: raising further capital, licensing technology, or being acquired by larger companies. As organisations grow and change, scientists often face choices about their own careers. One path is to deepen further as a specialist, focused primarily on the science. Another is to move into running teams, managing larger research budgets and taking on the responsibilities that come with leadership. Both are legitimate choices.

As a scientist working within that environment, you may find yourself navigating exactly those transitions and working out where your own role sits within a larger organisation or ecosystem. This is a far easier path to navigate if you have picked up some business fundamentals along the way.

The T-shaped scientist

This is what I mean by a T-shaped scientist. The vertical stroke of the T is your technical specialism, the deep and hard-won expertise that no short course could ever replace.

The horizontal stroke is a set of handlebars: a working understanding of a few key areas of business. You are not trying to become an expert in any of them. The whole point of the T is that this knowledge stays shallow by comparison with your technical depth, yet that small horizontal line makes you markedly more effective, because you begin to understand what the other people around the table are actually looking for. For example, when you know what a venture capitalist wants, you can pitch your contribution in the right direction and be understood.

If you feel you were never given any of this, you are right. Business fundamentals have not traditionally formed a significant part of life sciences degrees, or of pure science degrees more generally. Scientists, as a rule, arrive in their careers without this grounding, not because they were incapable of learning it, but because no one ever put it in front of them.

Where to focus first

So where might you start in your quest to become T-shaped? For a life scientist, it is helpful to pay attention to a few areas early in your career:

  • The first is learning to see the world beyond the laboratory: understanding your market, who the customer or end user is, how investors and commercial partners think, what they are looking for and over what timescales.
  • The second is financing, along with the wider business machinery that surrounds any funding round.
  • The third is the end-to-end route to market, which in the life sciences sector means the regulatory approval process and a clear sense of where your technology sits, such as on the scale of Technology Readiness Levels, or TRLs. These are the questions that decide whether good science ever becomes a product.

If you later decide to move into leadership in larger companies that so often acquire life science businesses, the list grows. It becomes worth understanding how venture capital works, the risks that attach to any technology, and why so many promising ideas run into market failure.

It also helps to grasp product-market fit and how customers really think, along with market segmentation, the life cycle of a technology product, the mechanics of fundraising and the basics of marketing.

Again, none of this replaces your science, but it does help you put it to greater use.

More within reach than you might think

The encouraging part is that far more of this is available than you might realise, and much of it costs very little.

If you are based in a university, your institution may well offer commercial awareness, entrepreneurship or innovation training, often through an enterprise team, technology transfer office or business school. Much of this support is free for researchers, although you may have to seek it out rather than wait for it to arrive.

Outside the university system it can take a little more effort, though the options are there. Help to Grow, the national business training programme, delivered through business schools, is open to eligible leaders and senior managers of UK SMEs, with the government covering 90 per cent of the fee.

For those already leading an eligible small business, the Goldman Sachs 10,000 Small Businesses UK programme is another route worth knowing. For university researchers, Innovate UK’s ICURe programme offers structured support to explore the commercial applications and potential markets for research.

When the next step is more formal

For some, the natural next step is a more formal one. An MBA is, in many respects, a preparation for exactly the future most life science ventures are heading towards: either raising more capital or becoming part of a much larger, often multinational, ecosystem. That transition is common in the life sciences sector, and an MBA is one of the best ways to be ready for it.

It is why ESBF funds scholarships for scientists and engineers who want to pursue an MBA, in partnership with leading business schools. We are aware that the costs of an MBA can be great and that this is a major barrier to scientists wishing to deepen their business education.

You do not have to want to be a CEO or an entrepreneur, but some handlebar shaped breadth, set alongside the vertical depth you already have, will make you T-shaped: a stronger collaborator, a clearer communicator and a more valuable scientist, whichever path you choose.

Often the first step is simply knowing that the option is there.

 

Author Bio

David Falzani MBE

    David Falzani MBE is President of Engineers and Scientists in Business Fellowship (ESBF) and Professor of Practice in Sustainable Wealth Creation at Nottingham University Business School. David has been a director or investor in over 16 entrepreneurial companies in four countries and has helped start-ups raise over £35m in venture capital investments. In his consultancy role he works with a variety of industries. He is currently a mentor and/or trainer for innovation and growth programmes such as the prestigious Goldman Sachs 10,000 Small Businesses programme at Oxford University Saïd Business School, Ingenuity programme at Nottingham University, and the Royal Academy of Engineering’s Leaders in Innovation Fellowship programmes. He has published over 80 articles and blogs. David’s book ‘Double Your Price!’ from FT Publishing has been shortlisted in the finals of the Business Book Awards 2024.
    References: Based on the author's professional experience. No external sources cited.
    All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions

    Articles that may be of interest

    Articles that may be of interest

    Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares

    Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares

    Anyone searching neladalkib vs lorlatinib will find no head-to-head trial. No published evidence yet shows which drug is better. What the data do show is narrower. The US Food and Drug Administration (FDA) granted accelerated approval to neladalkib, branded Nelkarmi,...

    read more
    OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

    OLN324 vs Vabysmo: How J&J’s $2.2bn Eye Drug Compares

    How does OLN324 compare with Vabysmo? In the only head-to-head data found, it dried the retina faster in diabetic macular oedema. However, differences in durability and vision were small. That evidence comes from a 164-patient Phase 1b trial, and no Phase 3 comparison...

    read more